Legal aspects of FDA regulatory Compliance: Preparing for an FDA Facility Inspection and Responding to a 483 Letter
May 18, 2020
Webinar
In addition to evaluating data from adverse event reports, the bulk of FDA’s regulatory enforcement comes from its facility inspections and resulting 483 reports. This practical webinar will cover numerous aspects of preparing your drug or medical device establishment for a successful FDA facility inspection and responding to any post-inspection 483 letters. The key to a successful inspection strategy is adequate preparation and implementing the inspection plan before FDA knocks on your door. Attendees will learn:
-
- What to expect during the inspection;
- Strategies for preparing for an inspection;
- What to expect after the inspection;
- Strategies for responding to any deficiencies noted in a 483 report;
- Potential product liability issues stemming from a 483 report.
Recent News
- Merit Medical Acquires Biolife Delaware
- Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis